注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
MeiraGTx Holdings plc是一家綜合臨床階段基因治療公司。該公司專注於三個未滿足的醫療需求領域,包括遺傳性視網膜疾病(ID),以及大型退行性眼病、嚴重的口乾症和神經退行性疾病。該公司的產品管線包括用於治療X連鎖視網膜色素變性(XLRP)的AAV-RPGR、用於治療二/三級放射性口乾症的AAV-hAQP1、用於治療帕金森病的AAV-GAD、用於治療色盲(ACHM)的AAV-CNGB3和AAV-CNGA3。該公司有六個臨床開發項目,包括色盲、X-連鎖色素性視網膜炎和RPE65缺陷的I/II期臨床階段項目,以及輻射誘發口乾症(RIX)的I期臨床試驗,以及帕金森氏症項目 完成了已公佈數據的II期試驗。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Chuan He | 51 | - | Member of Scientific Advisory Board |
Michael G. Kaplitt | - | - | Member of Scientific Advisory Board |
Nicole Seligman | 67 | 2019 | Independent Director |
Gregory A. Petsko | - | - | Chairman of Scientific Advisory Board |
Keith Reginald Harris | 70 | 2015 | Independent Chairman of the Board |
Arnold J. Levine | 83 | 2016 | Member of Scientific Advisory Board |
James C. Alwine | - | - | Member of Scientific Advisory Board |
Alexandria Forbes | 58 | 2015 | CEO, President & Director |
Kevin Weeks | - | - | Member of Scientific Advisory Board |
Brian Shoichet | - | - | Member of the Scientific Advisory Board |
Martin Indyk | 71 | 2019 | Independent Director |
Debra Yu | 58 | 2022 | Independent Director |
Stefano Rivella | - | - | Member of Scientific Advisory Board |
Thomas E. Shenk | 76 | 2015 | Independent Director & Member of Scientific Advisory Board |
Neil Mendoza | 63 | 2015 | Independent Director |
Lynne Elizabeth Maquat | - | 2019 | Member of Scientific Advisory Board |
Robert Batey | - | - | Member of Scientific Advisory Board |
Ellen Hukkelhoven | 36 | 2017 | Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核